Trader Joe's Cheese Recall in Two States as Warning Issued
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Face Rock Creamery voluntarily recalled two lots of its "Vampire Slayer Garlic Cheddar Curds" from Trader Joe's stores in northern California and northern Nevada this week after routine product tests revealed possible contamination with Listeria monocytogenes.
The company, headquartered in Bandon, Oregon, recalled its product on June 20 but the Food and Drug Administration (FDA) has yet to classify the recall.
Newsweek has contacted Face Rock Creamery outside of regular working hours via email for comment.
Why It Matters
Listeria monocytogenes infection, or listeriosis, may lead to high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea.
The bacterium poses a greater risk to young children, elderly people, those with compromised immune systems, and pregnant women, who may experience miscarriages or stillbirths if infected.
The Cleveland Clinic has identified soft cheeses, deli meats and unpasteurized dairy products as some of the foods that are more likely to be contaminated with listeria.
A file photo shows the affected product, which was sold in Trader Joe's stores.
A file photo shows the affected product, which was sold in Trader Joe's stores.
Uncredited/FDA
What To Know
The issue was discovered during routine sampling, which detected Listeria monocytogenes in finished product samples.
Face Rock Creamery notified the FDA and the Oregon Department of Agriculture and is continuing to work to identify the source of the contamination.
The affected product, "Vampire Slayer Garlic Cheddar Curds," were sold in 6-ounce sealed plastic cups with a lid and have a "Use By" date of August 29, 2025.
The product has a Universal Product Code of 8 51222 00528 7 and lot numbers 20250519VS01 and 20250519VS02.
The product was distributed at Trader Joe's stores in northern California (including locations in Monterey, Fresno, and all areas north) and northern Nevada (specifically in Carson City, Reno and Sparks).
As of the latest update, no consumers have reported any illnesses linked to the recalled product.
What People Are Saying
Face Rock Creamery said in its announcement: "Face Rock Creamery is committed to ensuring the safety and quality of our products and is working closely with our distribution partners and regulatory agencies to resolve the matter swiftly and thoroughly. We apologize for the inconvenience and appreciate the trust our customers place in us."
Cleveland Clinic says on its website: "Listeria is a bacterial infection that's more dangerous during pregnancy. It can cause pregnancy loss, lifelong illness in your child and newborn death. It causes flu-like and digestive symptoms. Avoiding foods like deli meats, soft cheeses and unpasteurized milk can reduce your risk."
What Happens Next
Anyone who purchased the affected product is strongly advised to refrain from consuming it and to return the product to the original point of purchase for a full refund.
Consumer questions can be directed to Face Rock Creamery's Customer Care team at info@facerockcreamery.com during regular business hours 8 a.m. to 5 p.m. PST.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
UK MHRA Approves ImmunityBio's ANKTIVA ® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. 'With the MHRA's authorization of ANKTIVA plus BCG, we can now offer our immunotherapy outside the U.S. to help patients with a disease that, if not effectively treated, can lead to bladder removal,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'This immune-boosting, lymphocyte-stimulating agent, the first of its kind, is central to our Cancer BioShield platform, which is designed to restore immune function and support long-term disease control.' 'ImmunityBio is honored to have received this important authorization from the UK MHRA. In light of the United States Most-Favored-Nation Prescription Drug Pricing policy implemented on May 12, 2025, we are actively evaluating our go-to-market strategy for the UK,' said Richard Adcock, CEO and President of ImmunityBio. ANKTIVA is a first-in-class IL-15 agonist that activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells. It is designed to restore immune competence by reversing lymphopenia—a condition in which cancer and conventional therapies, such as chemotherapy, radiation and checkpoint inhibitors, reduce the number and function of immune cells. Restoring immune function is essential for immunosurveillance, immunogenic cell death, and sustained tumor control. The BioShield platform's effectiveness can be monitored using a routine complete blood count (CBC). ANKTIVA was designated a Breakthrough Therapy by the FDA and received approval from both the FDA and MHRA based on its safety and efficacy outcomes of complete response (CR) and duration of response (DOR). In a single-arm, multicenter trial, 77 evaluable patients received ANKTIVA with BCG for up to 37 months. As of the November 2023 data cutoff, the duration of complete response for some patients exceeded 47 months and remains ongoing. These extended duration of complete responses beyond 24 months with ANKTIVA and BCG surpasses the benchmark for meaningful clinical results set by experts from the International Bladder Cancer Group. ImmunityBio has also submitted regulatory applications to the European Medicines Agency (EMA) to expand availability of ANKTIVA across the 27 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. About NMIBC CIS Bladder cancer is the 10th most commonly-diagnosed cancer globally, 2 and in the UK, the Action Bladder Cancer UK estimates approximately 23,000 patients are diagnosed annually. 1 At the time of diagnosis, about 80% of cases are non-muscle invasive bladder cancer (NMIBC), wherein the cancer is found only on the inner layer of the bladder wall. 3 The standard therapy for NMIBC is intravesical instillation (delivery to the bladder via a catheter) of Bacillus Calmette-Guerin (BCG). 4,5 BCG is a benign bacteria that induces an immune response in the bladder in proximity to the cancer cells, leading to clearance of the cancer in many patients. In ~30-40% of patients, however, BCG will fail, and in ~50% that initially respond, cancer will recur. 6 About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit INDICATION AND IMPORTANT SAFETY INFORMATION FROM THE FDA LABEL INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. For more information about ANKTIVA, please see the Full Prescribing Information at You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482) About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. References: Action Bladder UK. Non-muscle invasive bladder cancer. May 2021. Available at: World Cancer Research Fund. Bladder Cancer Statistics. 2022. Available at: Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 4(1), 56–64. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. Grabe-Heyne, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. PMID: 37503461; PMCID: PMC10369196. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the belief that the MHRA authorization leads to increased revenue, the expectation that the EAP as previously reported will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, and the impact of the MHRA on the Company's ex-United States go to market strategy, including in light of the recently implemented United States Most Favored Nation pricing policy on the Company's go-to-market strategy in the United Kingdom, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding regulatory submissions in foreign jurisdictions, filing and review process and the timing thereof, (iii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iv) risks and uncertainties regarding commercial launch execution, success and timing, (v) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (vi) whether clinical trials will result in registrational pathways and the risks, (vii) whether clinical trial data will be accepted by regulatory agencies, (viii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (x) ImmunityBio's ability to retain and hire key personnel, (xi) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
Business Upturn
6 hours ago
- Business Upturn
Luma Nutrition Magnesium Glycinate Surpasses 10,000 Monthly Sales on Amazon
Los Angeles, CA , July 07, 2025 (GLOBE NEWSWIRE) — Luma Nutrition is proud to announce that its flagship product, Luma Nutrition Magnesium Glycinate 1000mg, has officially surpassed 10,000 units sold per month on Amazon. As one of the best magnesium glycinate supplements available in 2025, this high-absorption formula continues to earn praise for its purity, effectiveness, and ability to support restful sleep, mental clarity, and full-body relaxation. The milestone underscores growing consumer demand for trusted, science-backed wellness solutions—and marks a major achievement for the Luma Nutrition brand. Check out Luma Nutrition's Magnesium Glycinate Capsules The Best Magnesium Glycinate? Magnesium plays a vital role in over 300 biochemical processes in the human body. From muscle function and nerve signaling to heart rhythm and bone development, it is a foundational mineral for optimal health. But not all magnesium forms are created equal. Magnesium Glycinate, a chelated form of magnesium bound to the amino acid glycine, is widely regarded as one of the most absorbable and gentle forms available. It is specifically formulated for individuals seeking a highly bioavailable magnesium supplement that won't cause gastrointestinal discomfort, unlike some other forms such as magnesium oxide or citrate. Save 15% when you subscribe and save with Luma Nutrition What Sets Luma Nutrition Apart Luma Nutrition's High Absorption Magnesium Glycinate Capsules are manufactured in FDA-registered facilities that comply with GMP (Good Manufacturing Practices) standards. Every batch is third-party tested, non-GMO, and made in the USA using pharmaceutical-grade ingredients. With a mission to support better health through science-backed nutrition, Luma Nutrition has created a supplement that delivers: Better Sleep Quality Stress Relief and Mood Support Muscle Recovery and Relaxation Enhanced Mental Clarity Nerve and Bone Health Support How to Use To get the most from your magnesium supplement, consistency is key. Luma Nutrition recommends taking 2 capsules in the evening with food. For optimal results, use daily for 1-3 months. This allows the body to rebalance its magnesium levels and begin experiencing the full range of benefits. What to Expect Over Time 1-2 Months: Initial Support & Relaxation Improved sleep quality Reduced nighttime awakenings Less muscle tension after exercise Noticeable stress relief and a calmer mood 3-6 Months: Deep Health Benefits Enhanced bone density Healthier blood pressure levels Stronger immune and metabolic functions Increased energy and vitality 6+ Months: Long-Term Wellness Consistent heart health maintenance Improved nerve signaling and neuromuscular coordination Support for managing chronic stress and fatigue Key Benefits 1. Alleviates Muscle Cramps Individuals with low magnesium levels often experience leg cramps or tension. Luma Nutrition's magnesium glycinate capsules can reduce both the frequency and intensity of these cramps, especially when taken regularly. 2. Supports Cardiovascular Health Magnesium helps regulate heartbeat, supports artery health, and facilitates the transport of electrolytes like calcium and potassium. A consistent intake promotes better heart health over time. 3. Boosts Bone Structure While calcium often gets the spotlight, magnesium is essential for bone formation. It helps convert vitamin D into its active form, supporting increased bone density and reducing the risk of osteoporosis. 4. Helps Manage Anxiety Magnesium stimulates the production of melatonin (the sleep hormone) and serotonin (the mood stabilizer). Together, these contribute to better emotional well-being and deeper, more restorative sleep. Why Choose Luma Nutrition for the Best Magnesium Glycinate Supplements? Luma Nutrition believes that true wellness is built on consistency, trust, and quality. The company sources only premium ingredients and formulates each product based on clinical research, and uphold the highest production standards. Luma Nutrition's Magnesium Glycinate is designed for individuals with real goals: better sleep, less stress, stronger bodies, and clearer minds. Here's why Luma Nutrition's product is ranked among the best magnesium glycinate supplements available in Canada and the United States: Third-Party Tested: Every batch is independently verified for potency and purity. GMP-Compliant: Produced in facilities that meet the highest manufacturing standards. Made in the USA: All ingredients are sourced and manufactured domestically. Non-GMO: Luma Nutrition uses only safe, clean ingredients free from harmful additives. Check out Luma Nutrition's Magnesium Glycinate Capsules 90-Day Satisfaction Guarantee Luma Nutrition offers a satisfaction guarantee. If customers are not satisfied within the first 90 days, they can contact Luma Nutrition's support team for a 100% money-back guarantee. Your wellness journey is risk-free with Luma Nutrition. How to Buy You can purchase Luma Nutrition's High Absorption Magnesium Glycinate Capsules directly from our official website or authorized online retailers. [SHOP NOW] to experience better sleep, better mood, and better health. Final Thoughts: The Best Magnesium Glycinate Supplements of 2025 Whether an individual is dealing with poor sleep, chronic stress, muscle tension, or simply want to optimize your health, magnesium glycinate is a top-tier supplement with clinically-backed benefits. In a crowded market, Luma Nutrition sets itself apart with a product that is clean, potent, and proven by thousands of satisfied customers. As 2025 unfolds, more people are choosing to invest in supplements that work with the body, not against it. For those seeking the best magnesium glycinate supplements, Luma Nutrition remains a top choice. Better sleep, less stress, and a stronger body await. Pros and Cons When considering this magnesium supplement, it's helpful to weigh its strengths alongside some potential drawbacks to make an informed choice. Pros High Absorption Formula: The chelated magnesium glycinate is designed for better uptake by the body, which supports muscle and nerve function more effectively. Vegan and Clean: Free from GMOs, gluten, and fillers, making it suitable for those with dietary restrictions or preferences. Balanced Dosage Options: Offers flexibility with a higher potency option per capsule, allowing users to adjust intake based on their needs. Made in the USA: Manufactured under strict quality standards with third-party testing, which adds confidence in its consistency and safety. Positive Sleep and Relaxation Support: Many users report improved sleep quality and relaxation effects without added sugars. Cons Price Point: This supplement can be more costly compared to other magnesium glycinate products on the market. Individual Response Varies: Some users do not experience noticeable effects within the first month, indicating that benefits may take time or differ by person. Capsule Count: A 30-day supply means regular repurchasing is required, which might be inconvenient for some. Possibility of Minor Side Effects: There are occasional reports of gastrointestinal discomfort, although this seems less common with this formula than others. Customer Reviews Most users find the supplement helpful for improving sleep quality and managing stress. Several report noticeable benefits within a few weeks, especially related to relaxation and muscle health. Some customers mention the product's price as higher compared to similar options. A few note no significant changes during initial use or mild gastrointestinal discomfort, but this varies individually. Pros Cons Improved sleep Slightly higher cost Supports muscle and nerve Effects not immediate Generally well absorbed Possible mild stomach issues Overall, the feedback leans positive with the majority appreciating its effectiveness over time. Tips for Optimal Supplement Use To get the most from a magnesium glycinate supplement, consistency is key. Taking it at the same time each day, preferably with food, can improve absorption and reduce stomach upset. Since the supplement is fairly potent, Starting with a lower dosage and adjusting as needed may help individuals avoid digestive discomfort. Staying hydrated supports magnesium's muscle and nerve benefits. It is helpful to monitor how the body responds over a few weeks before expecting noticeable effects, especially with sleep or stress support. If combined with other supplements, it is important to check for interactions to maintain safety. As individual needs vary, it is recommended that each person consult a healthcare provider to ensure the supplement fits their routine. Frequently Asked Questions Many people have questions about magnesium glycinate supplements before deciding to buy. Luma Nutrition gathered common queries and answered them to help clarify what this kind of supplement offers and what to consider. What are the benefits of taking magnesium glycinate supplements? Magnesium glycinate is known for its high absorption and gentle effect on the stomach compared to other magnesium forms. It supports muscle health, nerve function, and mental relaxation. Many users report improvements in managing muscle cramps and stress. While helpful for these areas, it's important to note that results vary individually, and consistency is key for noticeable effects. How does magnesium glycinate aid in improving sleep quality? Magnesium can help by calming the nervous system and promoting muscle relaxation, which may contribute to better sleep. The glycinate form often causes less digestive discomfort, making it a preferred choice when sleep support is the goal. However, its impact on sleep can be subtle and might take a few weeks to become apparent, depending on the user's unique body chemistry. Which brands are considered top-rated for magnesium glycinate supplements? Many top-rated brands focus on purity, potency, and third-party testing to ensure quality. Brands offering vegan, non-GMO, and gluten-free options tend to be favored. Higher customer ratings and transparent manufacturing practices often indicate reliable choices, but price and capsule form can vary significantly between brands. Are there specific magnesium glycinate supplements recommended for women? Some supplements are formulated with additional nutrients tailored for women's health, though magnesium glycinate itself is generally suitable for all adults. Women may prefer options labeled vegan and free from common allergens. It's wise to check if the supplement supports specific needs like hormone balance or prenatal health, but these usually involve products with added ingredients beyond magnesium glycinate. What should one look for when choosing a magnesium glycinate supplement? Key factors include: Purity: Avoid fillers, GMOs, and unnecessary additives. Dosage: Confirm the dose aligns with the individual's needs (commonly between 200–500 mg elemental magnesium). Form: Capsules or gummies based on personal preference. Certifications: Look for third-party testing, GMP certification, and clear ingredient sourcing. Also, consider the supplement's cost and supply duration to ensure it fits your routine and budget. Are there any notable differences between magnesium glycinate gummies and capsules? Capsules typically contain no added sugars or artificial flavors, appealing to those who want a straightforward, low-calorie option. Gummies offer easier consumption and taste better but often include sweeteners, which might not suit everyone. Absorption rates between the two forms are generally comparable, but personal preference and dietary restrictions often dictate which form is best to use. Press Inquiries [email protected] Benefits of Magnesium Glycinate Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
11 hours ago
- Yahoo
Even low doses of CBD may cause harm to the liver, FDA study finds
A new clinical trial suggests there are still ongoing questions about the safety of even low doses of cannabidiol, even as CBD capsules, gummies, edibles, oils and lotions have become increasingly omnipresent in the United States in recent years. Scientists from the Food and Drug Administration's Division of Applied Regulatory Science carried out a randomized double-blind placebo-controlled trial last year to assess how low-dose CBD affects liver function in a group of healthy middle-aged men and women. Over the course of four weeks, 201 volunteers received either 5 mg per kilogram of body weight (approximately 2.3 mg per pound or the equivalent of 350 mg for a 154-pound individual) of oral CBD, or a placebo. The goal was to give them a typical amount that might be used by consumers. Participants also underwent weekly laboratory assessments. While the vast majority of people in the trial were unaffected, 5% showed greatly elevated levels of the liver enzyme aminotransferase, a known marker of liver cell damage or inflammation, according to the study published Monday in JAMA Internal Medicine. Women appeared to be more vulnerable than men. The liver enzyme returned to normal within one or two weeks of stopping CBD. Seven participants withdrew from the trial because they were showing clinical signs of potential drug-induced liver injury. The FDA didn't respond immediately to a request for comment. 'This is a significant finding, as it suggests that CBD itself, even in the absence of other drugs, may pose a risk to liver health,' says Amir Englund, a researcher at King's College London who studies cannabinoid psychopharmacology, and was not involved in the new trial. 'The results have important implications for individuals using over-the-counter CBD supplements. Many may be unaware of the potential for liver injury and assume that CBD is entirely benign.' Between 2014 and 2022, CBD product sales in the U.S. increased from $108 million to $1.9 billion, after a landmark bill passed by the Trump administration in 2018 enabled the unrestricted sale of cannabis products containing less than 0.3% THC, the psychoactive element which gets users high. According to various surveys in recent years, the majority of people in the U.S. have now heard of CBD, and around 20% have reported using CBD products in the past 12 months. While CBD products have become a popular way to self-medicate for conditions including pain, anxiety, insomnia and depression, especially among older adults, there's been little evidence on how well they work or guidance on how to use the products safely. Signs of liver injury include abdominal discomfort, jaundice or yellowing of the skin and eyes, and fatigue. However, research has shown that drug-induced liver injuries don't always become immediately apparent. In the FDA trial, only one of the participants with elevated liver enzymes noticed any symptoms within four weeks. The authors suggested that users may not realize that they are incurring harm and that doctors should ask about regular CBD use as part of routine medical screening. 'This was an important observation from the study,' said Paul Watkins, professor of pharmacy at the University of North Carolina at Chapel Hill. 'When doctors get liver chemistry results back and they're out of whack, they should be aware to ask, 'Were you taking CBD?' Because a lot of people are.' The new trial is not the first study to suggest potential health risks relating to cannabidiol and its effects on the liver. Such concerns were initially described following an FDA review of clinical trial data on CBD-based prescription drugs for childhood epilepsy, with raised liver enzymes being observed in 14% of participants. 'In clinical trials involving epilepsy patients, elevated levels of liver enzymes were among the leading causes of withdrawal from the trials due to serious adverse events,' Englund said 'However, those participants were concurrently taking other anti-epileptic medications, which could have contributed to the observed liver effects.' Watkins was subsequently involved in research investigating why CBD can affect liver cells, and he said that certain doses seem to have an effect similar to acetaminophen, or paracetamol. 'It's interesting because it's also been shown that healthy adults, when they get recurrent therapeutic doses of paracetamol, also have these liver chemistry abnormalities,' Watkins said. In the U.S., acetaminophen, when taken in excess, is among the most common causes of drug-induced liver injury, also called toxic hepatitis. In the last few years, research studies have shown that people most at risk of liver injury are those taking very high oral doses of CBD, exceeding 1000 mg per day. There have still been reports of drug-induced liver injuries in some healthy individuals taking moderate doses of anywhere between 300 mg and 1000 mg per day. Relatively little is known about why some people are more susceptible than others, but it is thought that genetic factors may play a role. According to Englund, CBD can inhibit certain enzymes in the liver which are needed for metabolizing medications. In the new FDA trial, the majority of participants who experienced the most serious liver problems also developed signs of an immune condition called eosinophilia, which is when the body produces an excess of a type of white blood cell called eosinophils. The new results emphasize the importance of tracking liver safety as a potential, unintended adverse effect, Englund said. 'Given the growing interest in CBD as a potential treatment for conditions such as psychosis and cannabis use disorder, these findings underscore the importance of monitoring liver enzyme levels in future clinical trials,' he said. Overall, Watkins — who co-chairs the Drug-Induced Liver Injury Network, a research group backed by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health — still believes CBD is relatively safe. While over-the-counter supplements are becoming a growing potential cause of significant liver injuries, CBD has yet to be flagged as a source of concern, he said. 'Overall, the liver is very good at adjusting to sources of drug stress [indicated by elevated enzymes],' Watkins said, noting the network hasn't detected a case of serious liver injury attributed to CBD. "There could be people out there whose liver doesn't adjust very well, and as companies compete for market share, you might start getting more potent CBD which could push people into the ranges where they're getting into trouble, but the data we've got suggests it's very safe.' This article was originally published on
